| Date Filed | Type | Description |
| 08/10/2023 |
4
| Niederhuber John (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 3,571 restricted stock units
@ $0 |
|
| 08/10/2023 |
4
| Kunz Barbara Lopez (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 3,571 restricted stock units
@ $0 |
|
| 08/10/2023 |
4
| Harsanyi Zsolt (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 3,571 restricted stock units
@ $0 |
|
| 08/10/2023 |
4
| Grant Grady III (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 3,571 restricted stock units
@ $0 |
|
| 08/10/2023 |
4
| Abdun-Nabi Daniel (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 3,571 restricted stock units
@ $0 |
|
| 08/10/2023 |
4
| Taylor Daphne (SVP, CFO) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 6,945 restricted stock units
@ $0 |
|
| 08/10/2023 |
4
| Kwon SoYoung (SVP, GC, BD & Corp Affairs) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 9,375 restricted stock units
@ $0 |
|
| 08/10/2023 |
4
| Lamothe Jeffrey G. (EVP, COO) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 11,979 restricted stock units
@ $0
Exercised 1,833 restricted stock units
@ $0 |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/01/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/14/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/30/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/02/2023 |
4
| Grant Grady III (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 297 restricted stock units
@ $0
Granted 3,571 restricted stock units
@ $0 |
|
| 06/02/2023 |
4
| Kunz Barbara Lopez (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 297 restricted stock units
@ $0
Granted 3,571 restricted stock units
@ $0 |
|
| 06/02/2023 |
4
| Niederhuber John (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 297 restricted stock units
@ $0
Granted 3,571 restricted stock units
@ $0 |
|
| 06/02/2023 |
4
| Abdun-Nabi Daniel (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 297 restricted stock units
@ $0
Granted 3,571 restricted stock units
@ $0 |
|
| 06/02/2023 |
4
| Harsanyi Zsolt (Director) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 297 restricted stock units
@ $0
Granted 3,571 restricted stock units
@ $0 |
|
| 06/02/2023 |
4
| Kwon SoYoung (SVP, GC, BD & Corp Affairs) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 1,834 restricted stock units
@ $0 |
|
| 06/02/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/18/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/18/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/07/2023 |
4
| Lamothe Jeffrey G. (EVP, COO) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 3,666 restricted stock units
@ $0
Granted 16,500 restricted stock units
@ $0
Granted 16,500 options to buy
@ $2.15, valued at
$35.5k
|
|
| 03/07/2023 |
4
| Kwon SoYoung (SVP, GC, BD & Corp Affairs) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Exercised 3,666 restricted stock units
@ $0
Granted 11,000 restricted stock units
@ $0
Granted 11,000 options to buy
@ $2.15, valued at
$23.7k
|
|
| 03/07/2023 |
4
| Taylor Daphne (SVP, CFO) has filed a Form 4 on Aptevo Therapeutics Inc.|
Txns:
| Granted 11,000 options to buy
@ $2.15, valued at
$23.7k
Granted 11,000 restricted stock units
@ $0
Exercised 1,583 restricted stock units
@ $0 |
|
|